TFDP3 and neoplasm: In a previous clinical trial of peptide vaccination aimed at inducing tumor antigen-specific CD8+ and CD4+ T cells against NY-ESO-112, patients who were HLA-A*02:01+ (A2) and HLA-DPB1*04:01/*04:02+ (DP4) and had NY-ESO-1-expressing ovarian cancer were repeatedly vaccinated with a peptide, NY-ESO-1157–170 that contains highly immunogenic epitopes for A2 (NY-ESO-1157–165) and DP4 (NY-ESO-1157–170).